To investigate the molecules that regulate the acquisition of cis-diamminedichloroplatinum (II) (cisplatin) resistance, we performed cDNA microarrays using two pairs of parental and cisplatin-resistant bladder cancer cell lines. We found a markedly reduced expression of inositol 1,4,5-trisphosphate (IP 3 ) receptor type1 (IP 3 R1), endoplasmic reticulum membrane protein, in cisplatin-resistant cells. The suppression of IP 3 R1 expression using small interfering RNA in parental cells prevented apoptosis and resulted in decreased sensitivity to cisplatin. Contrarily, overexpression of IP 3 R1 in resistant cells induced apoptosis and increased sensitivity to cisplatin. These results suggest that cisplatin-induced downregulation of IP 3 R1 expression was closely associated with the acquisition of cisplatin resistance in bladder cancer cells.
Introduction
Cisplatin is generally accepted as a DNA-damaging agent and broadly used for anticancer drugs in many kinds of cancers, including those occurring in the testes, head, neck, esophagus, lung, ovary and bladder. However, the correlation between DNA adducts and cisplatin cytotoxicity has not yet been clarified (Burger et al., 1997; Vaisman et al., 1997) . The fact that approximately only 1% of intracellular cisplatin reacts with DNA (Eastman, 1983 (Eastman, , 1986 suggests that cisplatin may have other intracellular targets as an anticancer drug. Furthermore, the clinical uses of these drugs are often limited because of the appearance of cisplatinresistant tumor cells (Hisano et al., 1996) . The elucidation of the mechanisms that control the sensitivity to cisplatin is important to improve the therapeutic outcome. Various mechanisms have been shown to contribute to the cellular resistance to cisplatin. These mechanisms include the overproduction of detoxification factors such as thioredoxin (Yokomizo et al., 1995) , drug transporters such as multi-drug resistance-related proteins (MRPs) (Suzuki et al., 2001) , DNA repair enzymes (Masuda et al., 1988; Eastman and Schulte, 1998) , and apoptosis-related genes such as Bcl-2 or p53 (Eliopoulos et al., 1995; Niender et al., 2001) . However, the precise molecular mechanisms are still unclear.
Inositol 1,4,5-trisphosphate receptor type1 (IP 3 R1) is known as an IP 3 -gated Ca 2 þ channel that is located on the endoplasmic reticulum (ER). The ER stores intracellular Ca 2 þ and it has been reported to play a critical role in a variety of cell functions, including fertilization, cell proliferation, metabolism, secretion, contraction of smooth muscle, neural signals and apoptosis by pumping out Ca 2 þ from ER to cytosol (Berridge, 1993; Patel et al., 1999; Szalai et al., 1999; Demaurex and Distelhorst, 2003) . IP 3 R1-mediated Ca 2 þ spike is suggested to be a privileged signal for the induction of mitochondrial apoptosis (Szalai et al., 1999) . Indeed, the decreasing amount of IP 3 R1 by antisense RNA in Jurkat cells lead to significant inhibition of apoptosis (Jayaraman and Marks, 1997) . Contrarily, the overexpression of IP 3 R1 induces the increasing level of cytosolic Ca 2 þ and apoptosis (Szalai et al., 1999) . The concentration of intracellular-free calcium of the cisplatin-resistant lung cancer cell line has also been reported to be one-third that of the sensitive parental cell line (Liang and Huang, 2000) . These reports suggest the possibility that the IP 3 R1-mediated Ca 2 þ signaling is important in cisplatininduced apoptosis.
In this report, we performed cDNA microarrays in cisplatin-sensitive and -resistance bladder cancer cells, and we focused on the IP 3 R1 gene as one of the genes downregulated in cisplatin-resistant cells. We suggested that this is one reason why cisplatin initiates cells to develop acquired resistance to apoptosis.
Results

Gene expression profiling of the molecule that correlates with acquired cisplatin resistance
We performed cDNA microarray analyses between two kinds of bladder cancer cell lines, T24 and KK47 cells (Taya et al., 1977) , and their cisplatin-resistant cell lines, T24/DDP10 (Kotoh et al., 1994) and KK47/ DDP20 cells (Kotoh et al., 1997) , with or without cisplatin stimulation. The resistance to cisplatin of T24/DDP10 and KK47/DDP20 cells was, respectively, 8.4-and 18.7-fold that of the parental cells (Kotoh et al., 1994 (Kotoh et al., , 1997 . Using these cell lines, we screened 9182 genes. We found 51 genes downregulated in T24/DDP10 cells (Table 1) and nine genes downregulated in KK47/DDP20 cells (Table 2) , and five downregulated genes were common in two resistant cells. There were no common upregulated genes (Tables  1 and 2) . IP 3 R1 is one of the genes downregulated in resistant cells, and we preceded further analyses of IP 3 R1 in this report.
The lower expression of IP 3 R1 in resistant cells and the decreased expression of IP 3 R1 in parental cells after cisplatin exposure
Northern blot analysis shows that a spontaneous lower mRNA expression of IP 3 R1 was observed in resistant cell lines (Figure 1a) . A lower mRNA expression was also observed in resistant sublines, T24/DDP5 (Kotoh et al., 1994) and KK47/DDP10 cells (Kotoh et al., 1997) (data not shown). Similar results were obtained with regard to the protein expression level (Figure 1b 
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Upregulation of IP 3 R1 expression increases PARP cleavage in cisplatin-resistant cells
To confirm that IP 3 R1 modulates the sensitivity of cisplatin, we transiently transfected IP 3 R1 expression vector in cisplatin-resistant cell lines. We found that an overexpression of IP 3 R1 restored the cisplatin-induced PARP cleavage in T24/DDP10 cells ( Figure 4a ). Calcium ionophore A23187 also induced PARP cleavage in resistant cell lines ( Figure 4b ). MTS assay showed that the overexpression of IP 3 R1 in resistant cells resulted in increased sensitivity of cisplatin. The introduction of calcium ionophore also showed increased sensitivity in resistant cell lines ( Figure 4c ).
Discussion
To clarify the precise mechanism of cisplatin-induced resistance, it is necessary to avoid the clinical failure by cisplatin treatment. Several molecules that are associated with the acquisition of cisplatin resistance have been identified, including the glutathione metabolismrelated enzymes, metallothionein, thioredoxin, MRPs, DNA repair enzymes and apoptosis-related genes such as Bcl-2 or p53 (Masuda et al., 1988; Eliopoulos et al., 1995; Yokomizo et al., 1995; Eastman and Schulte, 1998; Niender et al., 2001; Suzuki et al., 2001) . In fact, intrinsically or artificially, overexpression or downregulation of these proteins contributes to change the sensitivity of cisplatin, and each protein bears each its own role to a greater or lesser degree. Therefore, to detect the molecules that show the change toward acquired cisplatin resistance in bladder cancer cells, we used a cDNA microarray analysis as a useful measure. Surprisingly, in our analyses, no significant differences were observed in thiols, drug transporters, DNA repair enzymes, and apoptosis-related genes (data not shown). Instead of these genes, IP 3 R1 showed markedly suppressed expression in cisplatin-resistant cells (Table 1 and 2 and Figure 1a ). IP 3 R1 has been reported to play a critical role in apoptosis (Szalai et al., 1999) . Three members of the IP 3 R family had reported (Newton et al., 1994) and targeted disruption of all three IP 3 R isoforms in the chick DT40 B-cell line-blocked Ca 2 þ mobilization and apoptosis by B-cell receptor crosslinking. Moreover, the degree of resistance increased with the number of IP 3 R genes deleted (Sugawara et al., 1997) . Jurkat cells deficient of IP 3 R1 do not induce apoptosis in response to dexamethasone, ionizing radiation, T-cell receptor, and Fas stimulation, and resist subsequent apoptosis (Jayaraman and Marks, 1997) . Our cDNA microarray analyses showed dominated expression of IP 3 R1 among IP 3 R families in both parental cells. The separate cDNA microarray analyses with cisplatin exposure showed the downregulation of IP 3 R1 and IP 3 R2 under cisplatin exposure in parental cells. IP 3 R3 expression was dominated in resistant cells but its expression level remained the same after cisplatin exposure ( Figure 5 ). These studies and our results, which showed that overexpression and suppression of IP 3 R1 modulate cisplatin sensitivity (Figures 3 and 4) , indicate that IP 3 R1 dominated the IP 3 R family in cisplatin-induced apoptotic pathway.
The regulation of Ca 2 þ is also achieved by the ryanodine receptor (RyR) and sarcoplasmic/ER Ca 2 þ -ATPase (SERCA) (Demaurex and Distelhorst, 2003) . RyR is important in the release of Ca 2 þ from ER to cytosol (Hajno´czky et al., 2000) , and SERCA pumped Ca 2 þ into the ER from cytosol (Pinton et al., 2001 ). However, our results showed no difference in the mRNA expressions of RyR and SERCA between parental and resistant cell lines (data not shown). Therefore, to determine the association between cisplatin-induced downregulation of IP 3 R1 expression and apoptosis, we modulated the expression of IP 3 R1, or the cytosolic concentration of Ca 2 þ by chemicals. Our results indicated that the downregulation of IP 3 R1 expression by IP 3 R1-si RNA or exposure of Ca by A23187, influenced cisplatininduced apoptosis in resistant cells (Figure 4) . The modulation of IP 3 R1 expression seems to be more effective than the control of cytosolic Ca 2 þ concentration by chemicals. Indeed, the IP3-linked mitochondrial apoptotic signal is suggested to be privileged as compared with other Ca 2 þ signals induced by Ca 2 þ buffering (Szalai et al., 1999) . Recent study shows that IP3R1 is regulated by transcription factor NF-AT (nuclear factor of activated T cells) (Furutama et al., 1996) . We also examined transcriptional activity under cisplatin exposure using the luciferase reporter assay; we found that cisplatin decreased the transcriptional activity of NF-AT in parental cell lines (data not shown). These results will support the IP 3 R1 mRNA downregulation by cisplatin.
The protein degradation by caspase-3 is one of the mechanisms that induce IP 3 R1 protein degradation (Hirota et al., 1999) . Actually, we observed a small amount of cleavage product of IP 3 R1 (data not shown); this may also be the reason that promotes the cisplatin resistance. Recently, Mandic et al. (2003) show that cisplatin induces ER stress by nucleus-independent apoptotic signaling. The other heavy metal, Manganese (II), which induces strong ER stress (Oubrahim et al., 2002) , decreased IP 3 R1 expression in parental cells (Figure 1d ). ER stress results in the accumulation of malfolded proteins; the cell triggers eIF-2a phosphorylation, which transiently halts general protein synthesis, giving the cell a chance to correct the environment within ER (Travers et al., 2000; Patil and Walter, 2001 ). The study that ER stress induced transcriptional suppression also may be the reason that the decreased IP 3 R1 expression is now in the process of investigation.
As a result, the mechanism regarding the acquisition of cisplatin resistance in T24 and KK47 cells is triggered due to a cisplatin-induced IP 3 R downregulation. Irreversible rapid downregulation of IP 3 R expression and the subsequent changes of Ca In conclusion, our findings will be useful for the development of new treatments through restoring apoptosis sensitivity by modulating the IP 3 R expression in cisplatin-resistant bladder cancer. Currently, cisplatin is regarded as one of the DNA-damaging agents and is still sometimes used for second-line treatment with other drugs even in cisplatin-resistant patients. Cisplatinresistant cells do not show crossresistance against the drugs, for example, DNA-damaging agents, etoposide (Kotoh et al., 1994; Mandic et al., 2003) . These properties suggest that the mechanisms of cisplatin resistance are not involved in the DNA adduct and that the more individualized selection of anticancer drugs is necessary for treatment of bladder cancer. Further analyses of IP 3 R1 expression level in patients before or after cisplatin treatment are presently in progress to confirm these findings and to use IP 3 R1 as the molecular marker to predict cisplatin sensitivity or as the therapeutical molecular target in the future.
Materials and methods
Drugs and antibodies
Cisplatin was obtained from the Nihon Kayaku Co. (Tokyo, Japan). A23187 and BAPTA-AM was from Sigma (Saint Louis, MI, USA). pCDNA3 and pCDNA3-IP 3 R1 were donated by Dr T Sudhof. Custom SMARTpoolt, IP 3 R1-si-RNA that selectively recognize IP 3 R1 among its family, and negative control, D-001206-13-05 Non-Targeting siRNA, were from Dharmacon (Lafayette, CO, USA). Anti-PARP p85 fragment antibody was from Promega (Madison, WI, USA). Anti b-actin antibody (sc-7210) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-IP 3 R1 (1157) antibody, which recognizes the C-terminal region, was from Sigma (Saint Louis, MI, USA).
Cell lines and cell culture
T24 and KK47 cell lines, established from human transitional cell carcinoma of the urinary bladder (Bubenik et al., 1973; Taya et al., 1977) , were used as parent lines. T24/DDP10 cells originated from T24 cells (Kotoh et al., 1994) , and KK47/ DDP20 from KK47 cells (Kotoh et al., 1997) were cultured as described previously (Kotoh et al., 1994 (Kotoh et al., , 1997 .
RNA preparations, cDNA microarray analyses, and data analyses Cells were harvested under exponential condition with or without 24 h cisplatin exposure, and the total RNA was isolated using an Isogen (Nippongene, Tokyo, Japan) according to the manufacturer's protocol. cDNA generation, hybridization, and data collection for cDNA microarray analyses were performed by the Incyte Corporation (Palo Alto, CA, USA). In brief, alterations in gene expression were evaluated by the reverse transcription of poly-(A) þ RNAs in the presence of Cy3 or Cy5 fluorescent-labeling dyes followed by hybridization to a UniGEM V 2.0 microarray chip. Each chip displays a total of 9182 elements, of which 8556 are unique genes/EST clusters. These unique gene/EST clusters can be further defined as 8412 annotated and 144 unannotated sequences. A 16-color log scale was used for visual representation and the differential expression (log 2) was determined for Cy3 signal: the signal of parental cell lines T24 and KK47 cells vs Cy5 signal: the signal of resistant cell lines T24/DDP10 and KK47/DDP20 cells as viewed in Incyte's GEM TM Tools software (Incyte Corporation). The subsets of genes were selected for further study based on differential Cy3/Cy5 expression ratios that were equal to or greater than 3.
Transfections and immunoblottings
T24 cells were transiently transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. The T24/DDP10 cells were transiently transfected using PolyFect transfection reagent (Qiagen, Tokyo, Japan) according to the manufacturer's protocol. Proteins were extracted using 1 Â SDS sample buffer containing 62.5 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 2% bmercaptoethanol, and 1 mM orthovanadate, at the indicated time points after cisplatin exposure. Equal amounts of total lysate were electrophoresed in 4-20% SDS-polyacrylamide gels, followed by transfer to a polyvinylidene fluoride membrane (Micron Separations Inc., Westborough, MA, USA). Western blotting was performed using the ECL system (Amersham, Buckinghamshire, England) with the antibodies described above. Each blot was performed at least five times using cell lysates extracted at different times with identical results. The RC DC Protein Assay (Bio-Rad, Hercules, CA, USA) was used for quantification of protein concentration according to the manufacturer's protocol. /well) were in 96-well flat bottom plates in 100 ml growth medium. Following 24 h incubation, each cell line was transfected as described above. At 24 h after transfection, cells were incubated in the presence of cisplatin at the indicated dose at 371C for 24 h. At 24 h after cisplatin exposure, the colorimetric reaction was initiated by adding 20 ml of CellTiter 96 s AQ ueous One Solution Reagent (Promega, Madison, WI, USA), which contains a novel tetrazolium compound (MTS) and electron coupling reagent (phenazine ethosulfate). Prior to the measurement, the plates were incubated for 3 h at 371C, and then the quantity of formazan products formed from MTS were measured by the amounts of 490 nm absorbance using an ELISA plate reader. All assays were performed in quadruplicate, and the mean values (7s.d.) were determined from three separate experiments. The results were shown as the percentage of control, while the absorbance of the untreated cells by cisplatin was considered to be 100%. For statistical analysis, we used Student's t-test.
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